Sector
PharmaceuticalsOpen
₹1,005Prev. Close
₹1,006.3Turnover(Lac.)
₹214.4Day's High
₹1,013.25Day's Low
₹993.9552 Week's High
₹1,09052 Week's Low
₹727Book Value
₹185.31Face Value
₹1Mkt Cap (₹ Cr.)
13,787.8P/E
45.62EPS
22.03Divi. Yield
02 Sep 2023
12:00 AM
BookCloser
14 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
7 Aug 2023
12:00 AM
AGM
Announcement Date: 07 Aug, 2023
Here are some of the stocks that may see significant price movement today: Hindustan Unilever, Birla Estates, Lupin, etc.
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 13.6 | 14.04 | 13.58 | 13.58 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 2,208.29 | 1,904.51 | 1,561.89 | 1,286.12 |
Net Worth | 2,221.89 | 1,918.55 | 1,575.47 | 1,299.7 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 1,215.73 | 1,108.83 | 1,020.23 | 760.6 |
yoy growth (%) | 9.64 | 8.68 | 34.13 | 6.69 |
Raw materials | -199.65 | -198.51 | -164.35 | -108.42 |
As % of sales | 16.42 | 17.9 | 16.1 | 14.25 |
Employee costs | -222.18 | -207.01 | -191.73 | -130.84 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 458.53 | 388.89 | 323.59 | 311.88 |
Depreciation | -51.45 | -37.64 | -44.88 | -21.79 |
Tax paid | -41.34 | -38.28 | -32.31 | -18.23 |
Working capital | 85.45 | 2.88 | 111.28 | 52.44 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 9.64 | 8.68 | 34.13 | 6.69 |
Op profit growth | 15.97 | 17.35 | 12.57 | 16.5 |
EBIT growth | 18.44 | 19.73 | 0.97 | 17.3 |
Net profit growth | 18.99 | 20.36 | -0.81 | 18.34 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 1,991.3 | 1,661.82 | 1,326.17 | 1,192.64 | 1,058.18 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,991.3 | 1,661.82 | 1,326.17 | 1,192.64 | 1,058.18 |
Other Operating Income | 17.85 | 23.33 | 20.88 | 19.22 | 15.88 |
Other Income | 23.82 | 11.15 | 26.09 | 8.71 | 15.4 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
CMD & Executive Director
Amit Indubhushan Bakshi
WTD & Executive Director
Kaushal Kamlesh Shah
WTD & Executive Director
Inderjeet Singh Negi
Executive Director / WTD / Chi
Krishnakumar Vaidyanathan
Independent Non Exe. Director
Sujesh Vasudevan
Independent Non Exe. Director
Prashant Gupta
Independent Non Exe. Director
Rajeev Narotam Dalal
Independent Non Exe. Director
Kalpana Unadkat
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by ERIS Lifesciences Ltd
Summary
Eris Lifesciences Limited was incorporated on January 25, 2007. Subsequently, the name of the company was changed to Eris Lifesciences Private Limited on February 9, 2007. Further, the Company was converted into a Public Limited cCompany and the name was changed to Eris Lifesciences Limited on February 2, 2017. The Company has a manufacturing plant in Guwahati, Assam and is presently engaged in manufacturing and marketing of pharmaceutical products. It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors. Apart from this, it has a portfolio of 112 Mother Brands across therapy areas. The company develops, manufactures and commercializes branded pharmaceutical products in selected therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market (IPM), such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infective. Its focus has been on developing products in the chronic and acute categories which are linked to lifestyle related disorders. Its operations are supported by a distribution network of 22 Sales depots, 2,059 Stockists and more than 5,00,000 retail chemists.In 2007, the company launched Eris division focused on cardiology and diabetes segment. In 2008, the company launched Nikkos division focused on gastroenterology and orthopedics segment. In 2009, the company launched Adura division focused on cardiology and diabetes
Read More
What is the ERIS Lifesciences Ltd share price today?
The ERIS Lifesciences Ltd shares price on N/A is Rs.₹1012.75 today.
What is the Market Cap of ERIS Lifesciences Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of ERIS Lifesciences Ltd is ₹13781.00 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of ERIS Lifesciences Ltd?
The PE and PB ratios of ERIS Lifesciences Ltd is 45.62 and 5.42 as of 22 Jul ‘24
What is the 52 Week High and Low of ERIS Lifesciences Ltd?
The 52-week high/low is the highest and lowest price at which a ERIS Lifesciences Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of ERIS Lifesciences Ltd is ₹727 and ₹1089.85 as of 22 Jul ‘24
What is the CAGR of ERIS Lifesciences Ltd?
ERIS Lifesciences Ltd's CAGR for 5 Years at 18.71%, 3 Years at 9.92%, 1 Year at 36.84%, 6 Month at 12.77%, 3 Month at 15.02% and 1 Month at -3.72%.
What is the shareholding pattern of ERIS Lifesciences Ltd?
The shareholding pattern of ERIS Lifesciences Ltd is as follows:
Promoters - 54.88 %
Institutions - 30.82 %
Public - 14.30 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
